Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAL: R-ICE vs R-DHAP and Rituximab Maintenance in Relapsed DLBCL
NCT00137995Phase 3Completed
- Sponsor
- Lymphoma Study Association
- Start
- Jun 2003
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Lymphoma Study Association. Primary endpoints: Mobilization Adjusted Response Rate at 3 months and Event Free Survival. Started Jun 2003; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00137995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137995.